Breaking News

Adverse Effects Identified Following Faricimab Treatment for Eye Conditions
Adverse Effects Identified Following Faricimab Treatment for Eye Conditions Oct 15, 2024 Researchers from the University Hospital Zurich have reported cases of sterile intraocular inflammation, including severe retinal vasculitis, associated with faricimab injections.
Eye Drop Company Faces FDA Scrutiny Again Over Unapproved Products
Eye Drop Company Faces FDA Scrutiny Again Over Unapproved Products Sep 19, 2024 The FDA has issued a warning letter to the Regenerative Processing Plant, manufacturer of Regener-Eyes Pro and Lite eye drops, for marketing unapproved products claiming to treat dry eyes.
Maestro®: The Sinusoidal IOL
Maestro®: The Sinusoidal IOL Sep 18, 2024 VSY Biotechnology introduced the Maestro® Sinusoidal IOL at ESCRS 2024, featuring SVT. This innovative trifocal lens enhances visual acuity, contrast sensitivity, and light transmission, offering a cutting-edge solution for presbyopia management.

 

a banner for OBN's Spotlight TV series. Showing 5 people in ophthalmic sector

Industry News

Opthea Announces Leadership Changes as it Prepares for Phase 3 Data on Sozinibercept
Opthea Announces Leadership Changes as it Prepares for Phase 3 Data on Sozinibercept Sep 06, 2924 Opthea has announced key leadership appointments to strengthen its commercial and clinical capabilities as it prepares for the 2025 topline data readout of Phase 3 trials for sozinibercept, its lead candidate for wet AMD.
BlueRock Therapeutics Receives FDA Clearance for OpCT-001 IND Application
BlueRock Therapeutics Receives FDA Clearance for OpCT-001 IND Application Sep 05, 2924 BlueRock Therapeutics, a subsidiary of Bayer, announced that the FDA has cleared its investigational new drug (IND) application for OpCT-001, a stem cell therapy designed to treat primary photoreceptor diseases.
Ophthalmic Drug Delivery Summit to Convene in San Francisco
Ophthalmic Drug Delivery Summit to Convene in San Francisco Oct 15, 2024 In January, over 60 world-renowned experts in ophthalmic drug delivery will gather in San Francisco for the 3rd annual Ophthalmic Drug Delivery Summit.

Ophthalmic Research News

Color Vision Deficiency May Affect Diagnosis of Choroidal Conditions
Color Vision Deficiency May Affect Diagnosis of Choroidal Conditions Sep 24, 2924 Color vision deficiency (CVD) can affect an ophthalmologist’s ability to differentiate between choroidal melanoma and choroidal nevus, potentially leading to misdiagnoses.
The Relationship Between Blood Pressure and Intraocular Pressure in Glaucoma Risk
The Relationship Between Blood Pressure and Intraocular Pressure in Glaucoma Risk Oct 01, 2024 Evidence suggests that ocular perfusion pressure is a strong risk factor for glaucoma. Ocular perfusion pressure is the relationship between the eye pressure and the blood pressure.
Nicotine's Potential in Myopia Control: Animal Research Findings
Nicotine's Potential in Myopia Control: Animal Research Findings Sep 27, 2024 Researchers led by Dr. Kate Thomson from the University of Canberra have found that nicotine, when administered either as an intravitreal injection or topical eye drop, significantly inhibited the development of FDM and LIM in chicks.

Ophthalmic Blog

Global Myopia Rates in Children and Teens Expected to Surpass 740 Million by 2050
Global Myopia Rates in Children and Teens Expected to Surpass 740 Million by 2050 Oct 01, 2024 A new analysis published in the British Journal of Ophthalmology reveals that nearly one in three children and teens worldwide is expected to be affected by myopia by 2050, translating to over 740 million cases.
Lamprey's Eye Disease: Separating Fact from Fiction
Lamprey's Eye Disease: Separating Fact from Fiction Sep 30, 2024 Lamprey Eye Disease, also known as "Lamprey Disease," is a hoax that has been circulating on the internet for several years. The hoax claims that a parasitic fish known as the lamprey is responsible for a disease that can cause blindness in humans.
ChatGPT-4.0 Demonstrates Promise in Addressing Retinal Disease Queries
ChatGPT-4.0 Demonstrates Promise in Addressing Retinal Disease Queries Aug 27, 2024 A recent study highlights the potential of ChatGPT-4.0 in accurately answering questions related to retinal diseases, covering diagnostic criteria, treatment guidelines, and management strategies.
Ophthalmology Breaking News Subscribe